Programmed Cell Death 1 Receptor
"Programmed Cell Death 1 Receptor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An inhibitory T-lymphocyte receptor that has specificity for CD274 ANTIGEN and PROGRAMMED CELL DEATH 1 LIGAND 2 PROTEIN. Signaling by the receptor limits T cell proliferation and INTERFERON GAMMA synthesis. The receptor also may play an essential role in the regulatory pathway that induces PERIPHERAL TOLERANCE.
Descriptor ID |
D061026
|
MeSH Number(s) |
D12.776.543.750.705.222.875 D23.050.301.264.894.790 D23.101.100.894.790
|
Concept/Terms |
Programmed Cell Death 1 Receptor- Programmed Cell Death 1 Receptor
- PD-1 Receptor
- PD 1 Receptor
- Receptor, PD-1
- CD279 Antigen
- Antigen, CD279
- PD1 Receptor
- Receptor, PD1
- Programmed Cell Death 1 Protein
- Antigens, CD279
- CD279 Antigens
|
Below are MeSH descriptors whose meaning is more general than "Programmed Cell Death 1 Receptor".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptors, Immunologic [D12.776.543.750.705]
- Costimulatory and Inhibitory T-Cell Receptors [D12.776.543.750.705.222]
- Programmed Cell Death 1 Receptor [D12.776.543.750.705.222.875]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Surface [D23.050.301]
- Antigens, Differentiation [D23.050.301.264]
- Antigens, Differentiation, T-Lymphocyte [D23.050.301.264.894]
- Programmed Cell Death 1 Receptor [D23.050.301.264.894.790]
- Biomarkers [D23.101]
- Antigens, Differentiation [D23.101.100]
- Antigens, Differentiation, T-Lymphocyte [D23.101.100.894]
- Programmed Cell Death 1 Receptor [D23.101.100.894.790]
Below are MeSH descriptors whose meaning is more specific than "Programmed Cell Death 1 Receptor".
This graph shows the total number of publications written about "Programmed Cell Death 1 Receptor" by people in this website by year, and whether "Programmed Cell Death 1 Receptor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2003 | 0 | 1 | 1 |
2005 | 0 | 1 | 1 |
2007 | 0 | 1 | 1 |
2009 | 0 | 2 | 2 |
2010 | 0 | 3 | 3 |
2011 | 1 | 2 | 3 |
2012 | 2 | 2 | 4 |
2013 | 7 | 0 | 7 |
2014 | 3 | 4 | 7 |
2015 | 8 | 4 | 12 |
2016 | 7 | 17 | 24 |
2017 | 24 | 19 | 43 |
2018 | 30 | 25 | 55 |
2019 | 30 | 32 | 62 |
2020 | 31 | 40 | 71 |
2021 | 19 | 15 | 34 |
2022 | 6 | 28 | 34 |
2023 | 5 | 12 | 17 |
2024 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Programmed Cell Death 1 Receptor" by people in Profiles.
-
Differential Upregulation of Th1/Th17-Associated Proteins and PD-L1 in Granulomatous Mycosis Fungoides. Cells. 2024 Feb 27; 13(5).
-
PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-?B Signaling in Patients with Pancreatic Cancer. Clin Cancer Res. 2024 02 01; 30(3):542-553.
-
Antigen-presenting B cells promote TCF-1+ PD1- stem-like CD8+ T-cell proliferation in glioblastoma. Front Immunol. 2023; 14:1295218.
-
Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study. Cancer Res Commun. 2023 12 19; 3(12):2572-2584.
-
Galectin-3 predicts acute GvHD and overall mortality post reduced intensity allo-HCT: a BMT-CTN biorepository study. Bone Marrow Transplant. 2024 Mar; 59(3):334-343.
-
Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer. J Immunother Cancer. 2023 11; 11(11).
-
The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial. Nat Med. 2023 Nov; 29(11):2814-2824.
-
PD-1 blockade in combination with dasatinib potentiates induction of anti-acute lymphocytic leukemia immunity. J Immunother Cancer. 2023 10; 11(10).
-
Endoscopic and imaging outcomes of PD-1 therapy in localised dMMR colorectal cancer. Eur J Cancer. 2023 11; 194:113356.
-
PD-1 blockade increases the self-renewal of stem-like CD8 T cells to compensate for their accelerated differentiation into effectors. Sci Immunol. 2023 08 04; 8(86):eadg0539.